NCT06564324Phase 3Recruiting

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Study sponsor: Nuvation Bio Inc. · NUVB

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-01Estimated
Enrollment · participants194Estimated
Source updated2026-04-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Planned enrollment increased by 56 participants

Before: 138 participants (planned). After: 194 participants (planned).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview